Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Other Operating Expenses (2021 - 2025)

Historic Other Operating Expenses for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Q3 2025 value amounting to $25.5 million.

  • Mirum Pharmaceuticals' Other Operating Expenses rose 2273.86% to $25.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.8 million, marking a year-over-year increase of 1296.21%. This contributed to the annual value of $81.6 million for FY2024, which is 7356.45% up from last year.
  • Mirum Pharmaceuticals' Other Operating Expenses amounted to $25.5 million in Q3 2025, which was up 2273.86% from $23.4 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' Other Operating Expenses' 5-year high stood at $25.5 million during Q3 2025, with a 5-year trough of $1.9 million in Q4 2021.
  • In the last 5 years, Mirum Pharmaceuticals' Other Operating Expenses had a median value of $14.0 million in 2023 and averaged $13.4 million.
  • In the last 5 years, Mirum Pharmaceuticals' Other Operating Expenses skyrocketed by 45674.23% in 2023 and then plummeted by 895.28% in 2024.
  • Over the past 5 years, Mirum Pharmaceuticals' Other Operating Expenses (Quarter) stood at $1.9 million in 2021, then skyrocketed by 136.15% to $4.5 million in 2022, then soared by 456.74% to $25.0 million in 2023, then dropped by 8.95% to $22.8 million in 2024, then increased by 12.1% to $25.5 million in 2025.
  • Its Other Operating Expenses stands at $25.5 million for Q3 2025, versus $23.4 million for Q2 2025 and $23.0 million for Q1 2025.